Global pharmaceutical services firm Clinigen appointed Greg Skalicky as Group Chief Executive Officer on July 20, 2026. Skalicky replaces Dr. Varun Sethi, who led the organization as Acting CEO since September 2025. Furthermore, the industry veteran brings over three decades of commercial and clinical experience.
In his new role, Skalicky will lead operational expansion into global markets. He previously was President of Eversana, where he built integrated commercialization frameworks. He also has executive experience at Syneos Health and Pharmanet. As a result, Clinigen will use his strategic leadership to expand global operations.
Strategic Expansion for Global Healthcare Access
Currently, Clinigen serves more than 1,000 biotechnology and pharmaceutical partners across five continents. Under Skalicky, Clinigen aims to enhance client value and expand compassionate use programs.
“Greg is an accomplished healthcare executive with deep industry expertise and a proven ability to scale global organisations,” said Paul Carter, Chairman of Clinigen. “His extensive experience across commercialisation, patient access, and pharmaceutical services makes him exceptionally well positioned to lead Clinigen into its next chapter. Our ambition is to offer pharma and biotech clients a fully integrated partner to deliver access to critical medicines across the pharmaceutical lifecycle, and Greg’s experience positions him perfectly to deliver on that vision. I would like to thank Varun for his outstanding leadership as Acting CEO, during which time he has continued to strengthen the business and advance our strategic priorities.”
Moreover, Clinigen continues to focus on supply chain innovation and market growth.
“I am honoured to join Clinigen at such an exciting time in the company’s evolution,” said Greg Skalicky. “Clinigen has built an outstanding reputation for solving some of the most complex access and supply challenges in healthcare. The company’s mission, expertise, and commitment to patients deeply resonate with me. I look forward to working alongside our talented global team to accelerate growth, enhance client value, and expand access to critical medicines for patients around the world.”
The leadership transition also coincides with Clinigen accelerating its wider long-term growth initiatives in key international markets. Clinigen continues to expand its global infrastructure, integrating its clinical trial supply capabilities with its extended managed access networks. This positions the company well to accelerate access for life-saving therapies to healthcare providers and biopharmaceutical partners across the globe.
For more stories on executive leadership and business innovations, explore our CXO Insiders for the latest updates.
Source: Businesswire
